Akèy › Myelom Miltip › Minnesota › Rochester
Etid klinik pou Myelom Miltip nan Rochester, MN
24 etid pou Myelom Miltip ap chèche patisipan nan sit nan ak bò kote Rochester (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
SMS-Based Remote Symptom Monitoring for Patients With Plasma Cell Disorders
Ap rekriteEtid obsèvasyon
- Mayo Clinic in Rochester, Rochester
A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)
Ap rekriteFaz 3
- Mayo Clinic, Rochester
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
Ap rekriteFaz 3
- Mayo Clinic Rochester, Rochester
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
Ap rekriteFaz 3
- Mayo Clinic, Rochester
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
Ap rekriteFaz 4
- Mayo Clinic Rochester, Rochester
Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma
Ap rekriteFaz 1
- Mayo Clinic in Rochester, Rochester
A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
Ap rekriteFaz 2/3
- Mayo Clinic Hospital Rochester /ID# 277886, Rochester
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
Ap rekriteFaz 2
- Mayo Clinic in Rochester, Minnesota, Rochester
Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
Ap rekriteFaz 1
- Mayo Clinic Rochester, Rochester
Dasatinib and Quercetin With CAR-T Therapy for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma
Ap rekriteFaz 2
- Mayo Clinic in Rochester, Rochester
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
Ap rekriteFaz 3
- Mayo Clinic in Rochester, Rochester
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
Ap rekriteFaz 1
- Mayo Clinic - Transplant Center - Rochester, Rochester
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
Ap rekriteFaz 1/2
- Research Site, Rochester
Understanding the Mechanisms of Clonal and Non-clonal Cytopenia Following CAR-T Therapy for Multiple Myeloma or CD19+ Lymphoproliferative Disorder (LPD)
Ap rekrite
- Mayo Clinic in Rochester, Rochester
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
Ap rekriteFaz 2
- Mayo Clinic - Minnesota, Rochester
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
Ap rekriteFaz 1
- Mayo Clinic in Rochester, Minnesota, Rochester
A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
Ap rekriteFaz 1
- Mayo Clinic - Rochester /ID# 251164, Rochester
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
Ap rekriteFaz 1
- Mayo Clinic, Rochester
Elotuzumab, Daratumumab, Iberdomide, and Dexamethasone for the Treatment of Relapsed Multiple Myeloma
Ap rekriteFaz 1/2
- Mayo Clinic in Rochester, Rochester
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
Ap rekriteFaz 3
- Mayo Clinic in Rochester, Rochester
A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma
Ap rekriteFaz 1
- Mayo Clinic in Rochester, Rochester
Remote Monitoring With Health-Coaching to Improve Quality of Life in Older Patients With Multiple Myeloma
Ap rekrite
- Mayo Clinic in Rochester, Rochester
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
- Mayo Clinic, Rochester
Family Study of Lymphoproliferative Disorders
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
- Mayo Clinic, Rochester
Etid Myelom Miltip nan lòt vil
- New York City, NY60 etid
- Boston, MA42 etid
- Atlanta, GA41 etid
- Houston, TX38 etid
- Durham, NC37 etid
- Nashville, TN32 etid
- Denver, CO26 etid
- Columbus, OH24 etid
- Baldwin Park, CA23 etid
- St. Louis, MO23 etid
- Washington, DC22 etid
- Chicago, IL22 etid
Lòt etid nan Rochester
- Kansè nan tete42 etid
- Kansè Poumon ki pa ti selil37 etid
- Kansè (tout kalite)30 etid
- Kansè Metastatik30 etid
- Kansè ovè29 etid
- Kansè kolorektal29 etid
- Kansè pankreyas23 etid
- Ensifizyans kadyak22 etid
- Kansè pwostat22 etid
- Kansè poumon20 etid
- Kansè Endomèt19 etid
- Lukemi lenfositè kwonik19 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 1, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.